Challenging Cases: 84yo WM w/AS, did TAVR. Used single Proglide in LCFA. Proglide got stuck and foot plate mechanism would not disengage from Ca+. We deconstructed and safely removed from the arteriotomy. Fantastic tips & tricks, big credit to Dr Amy Daliman TAVR Bot⁩

In Oct, 1000s will attend #TCT2023 at Moscone Ctr in SF. But most don't know that in Spring 1977, the 1st coronary angioplasties were done just 4 mi away. Before doing the 1st PTCA in the cath lab, Gruentzig tested his device w/Richard Myler on intraoperative cases. #AngioHistory

You betcha, Minnesota! The Land of 10,000 Lakes' best and brightest building their own custom wires with Asahi's finest. DM us direct to book your #build-a -wire event in your town! #CardiovascularFellowship #MinnesotaMedEd #AsahiFellowLife

ASPARTAME a Non-nutritive sweetener! (NNS) NNS are named so as their caloric value is negligible as compared to table sugar! Aspartame is 200 times sweeter than sugar! Acceptable daily intake (ADI) = 50 mg/kg/day ADI is usually set at 1/100th of toxic dose for safety purposes

Final year of training completed at a great place! #InterventionalCardiology

I dont usually debunk what health-illiterate spiritual gurus mutter about medicine and nutrition, but this video was shared with me for some fact checking and also because it has got millions of views and 60K likes. And it is utter nonsense. The video features Jaggi Vasudev,

Warm welcome to our new #BMCCardiovascDisord Editorial Board Members Tommaso Bucci from Sapienza Univeristy of Rome and Khalid Changal from MercyOne Siouxland. We look forward to working with you! Interested in joining #BMCCardiovascDisord? Visit <bmccardiovascdisord.biomedcentral.com/join-our-edito…>.

Late breaking at #ESCCongress: In a trial involving older patients with myocardial infarction and multivessel disease, physiology-guided complete revascularization led to a lower risk of cardiac events than culprit-only PCI. Full results of the FIRE trial:

VERY unexpected - INCREASED (!) bleeding risk if switching elderly frail patients from traditional Vit K antagonist anticoagulation to a NOAC FRAIL-AF trial #ESCCongress

If I was diagnosed with atrial myxoma, how long would it be before I saw a clip from my echo in a tweet that read “Diagnosis?”

Another great CTO live course at Emory. Thanks to ⁦Medtronic⁩ for support and the wonderful staff and faculty. ⁦William Nicholson⁩ Medtronic Cardiac⁩ ⁦Pratik Sandesara MD⁩ ⁦Stéphane Rinfret, MD SM⁩

3) BYPASS-CTCA, a RCT that randomised pts with previous CABG requiring invasive coronary angiography to either CTCA before ICA or ICA alone Link: ahajournals.org/doi/abs/10.116…

I continue to think about the serious situation in Palestine and in Israel where many, many people have lost their lives. In God’s name, I beg you to stop: cease using weapons! I hope that avenues will be pursued so that an escalation of the conflict might be absolutely avoided.

Presented at #AHA23: ORBITA-2 trial: In patients with stable angina who were receiving little or no antianginal medication and had documented ischemia, PCI resulted in a better health status with respect to angina than placebo at 12 weeks. Full results: nej.md/3u21tO2

#Totalityofdata IVI versus angio-guided PCI meta just published The Lancet. We knew IVI reduces every 2,3 & 4 letter word, but now the 5 letter word - DEATH. See for yourself authors.elsevier.com/c/1ie90V-4XL6EY #imagefirst #MLDMAX #OCT=#IVUS Gregg W. Stone MD OPCI Evald Høj Christiansen Niels R. Holm

1/4 Just publ in the Lancet our updated network meta-analysis of imaging-guided (OCT or IVUS) vs. angio-guided PCI across the spectrum of CAD. With 22 RCTs and 15,964 pts this is the 1st study to demonstrate that imaging reduces all-cause death (by 25%), as well as all MI (17%).

After 10 years to complete it, the DanGer-SHOCK trial showed that the routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The

In the DanGer Shock randomized trial, including 360 patients with STEMI complicated by cardiogenic shock, Impella reduced 180-day all-cause death from 59% to 46% (p=0.04, NNT=8), and a composite endpoint of escalation of treatment to additional MCS, heart transplantation, or

The PREVENT trial showed that preventive #PCI of focal non-FFR-positive plaques that are angiographically >50% & have evidence of vulnerability on intravascular imaging along w/ OMT is superior to OMT for clinical outcomes at 2 years. Read more: bit.ly/3xuHWrl #ACC24

Center for Coronary Artery Disease JM Schussler, MD Mauricio G. Cohen MD Hasan Jilaihawi Ankitkumar Patel MD MPH FACC FSCAI RPVI Mazen Albaghdadi MD MSc Khalid Changal Gauravpal Singh Gill Paul Nadira Hamid Konstantinos Voudris R. Jay Widmer Pedro E.P. Carvalho, MD Deniz Mutlu Sandeep Jalli Ahmed Al-Ogaili Michaella Alexandrou Salman Allana, MD FACC FSCAI